{"id":7518,"date":"2026-06-26T11:17:44","date_gmt":"2026-06-26T08:17:44","guid":{"rendered":"https:\/\/oncomsi.com\/tedavilerimiz\/metronomik-kemoterapi\/"},"modified":"2026-09-29T18:35:45","modified_gmt":"2026-09-29T15:35:45","slug":"metronomic-chemotherapy","status":"publish","type":"services","link":"https:\/\/oncomsi.com\/en\/treatments\/metronomic-chemotherapy\/","title":{"rendered":"Metronomic Chemotherapy"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"7518\" class=\"elementor elementor-7518 elementor-5841\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-d3af33f elementor-section-boxed elementor-section-height-default elementor-section-height-default default\" data-id=\"d3af33f\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-no\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-8a9aff2\" data-id=\"8a9aff2\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-6d9adbe elementor-widget elementor-widget-themeht-heading\" data-id=\"6d9adbe\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"themeht-heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\r\n        <div class=\"\">\r\n\r\n          <h1 class=\"mb-0 \">Metronomic Chemotherapy Low-Dose Continuous Treatment\n<\/h1>       \r\n\r\n        <\/div>\r\n\r\n        \t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-fc77901 elementor-widget elementor-widget-text-editor\" data-id=\"fc77901\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p class=\"geo-quick-answer\"><b>Metronomic chemotherapy<\/b> is a <b>cancer treatment approach<\/b> in which <b>chemotherapy<\/b> drugs are given at low doses, between roughly one-tenth and one-third of the standard dose, without breaks and mostly by mouth. It suppresses the blood vessel growth that feeds the tumor, shifts the immune balance in the patient&#8217;s favor and generally aims to keep the disease under control with fewer side effects than standard chemotherapy.<\/p><ul><li><strong>Dose:<\/strong> about 1\/10 to 1\/3 of the maximum tolerated dose<\/li><li><strong>Administration:<\/strong> daily or weekly, uninterrupted, mostly by mouth<\/li><li><strong>Target:<\/strong> tumor blood supply and microenvironment (anti-angiogenic effect)<\/li><li><strong>Cancers most studied:<\/strong> recurrent ovarian cancer, metastatic breast cancer, advanced pancreatic cancer<\/li><li><strong>Advantage:<\/strong> fewer side effects, can be continued as an outpatient and at home<\/li><\/ul><p>Metronomic chemotherapy is a cancer treatment approach based on giving chemotherapy drugs at much lower doses instead of standard high doses, continuously or at very short intervals, over a long period. The aim is not to hit the tumor with a single high-dose blow, but to build sustainable control by suppressing blood vessel growth, cutting off the tumor&#8217;s supply and shifting the immune balance in the patient&#8217;s favor. At ONCOMSI, metronomic chemotherapy is considered as part of an integrative treatment roadmap coordinated by the medical oncologist.<\/p><p>On this page you will find what metronomic chemotherapy is, how it works, which drugs are used, which cancer types and which patients it is considered for, its side effect profile and how the treatment process works in Istanbul.<\/p><h2>What Is Metronomic Chemotherapy?<\/h2><p>In conventional chemotherapy, drugs are given at amounts close to the highest dose the body can tolerate (maximum tolerated dose, MTD), with rest periods in between. These rest periods are needed for fast-dividing healthy tissues such as the bone marrow and digestive system to recover. Metronomic chemotherapy does the opposite: it gives drugs at low doses ranging from roughly one-tenth to one-third of the MTD, without breaks.<\/p><p>The word &#8220;metronomic&#8221; comes from the steady, continuous beat of the metronome in music. In this approach the drug is usually taken by mouth, daily or weekly, and a low but continuous blood level is maintained without sudden peaks and troughs. Because low doses do less harm to normal cells, treatment can often be continued as an outpatient without hospital admission.<\/p><p>In this respect metronomic chemotherapy is a strategy that questions the clich\u00e9 &#8220;a lower dose means less effect.&#8221; The goal is not rapid tumor shrinkage but to wear the tumor down biologically and preserve quality of life while keeping the disease under control. For a closer look at how lowering the dose changes treatment, see <a href=\"\/en\/low-dose-chemotherapy\/\">low-dose chemotherapy<\/a>.<\/p><h2>Why Was Metronomic Chemotherapy Developed?<\/h2><p>High-dose chemotherapy can shrink tumors quickly, but it brings problems such as severe side effects, hospital admissions, mandatory treatment breaks and regrowth of resistant tumor cells during those breaks. In the standard approach, the most resistant tumor cells may have a chance to recover during the long breaks that follow a high dose.<\/p><p>The idea of metronomic chemotherapy arose from the observation that chemotherapy drugs can target not only tumor cells but also the cells lining the inside of blood vessels (endothelial cells) that form the new vessels feeding the tumor. Because endothelial cells divide more slowly than tumor cells, standard intermittent treatments do not affect them enough. When the drug is given at a low dose but without breaks, endothelial cells are not allowed to repair and recover, and vessel growth is kept under constant pressure.<\/p><h2>How Does Metronomic Chemotherapy Work?<\/h2><p>Metronomic chemotherapy is a multi-targeted treatment based not on a single mechanism but on several complementary effects. The main pathways highlighted in the scientific literature are:<\/p><h3>1. Suppressing blood vessel growth (anti-angiogenic effect)<\/h3><p>Solid tumors need a new vascular network to grow beyond a certain size. Continuous low-dose chemotherapy selectively suppresses the proliferation of endothelial cells and may reduce the signals that promote vessel formation (for example VEGF). An increase in molecules that block vessel formation, such as thrombospondin-1, and a fall in bone marrow-derived vascular progenitor cells play a role in this process. As a result, the tumor&#8217;s oxygen and nutrient supply is restricted.<\/p><h3>2. Regulating the immune system (immunomodulation)<\/h3><p>Tumors can increase the number of regulatory T cells (Tregs) to suppress the immune system in their favor. Metronomic chemotherapy, especially low-dose cyclophosphamide, can reduce these suppressive Tregs, increasing the activity of the cytotoxic T cells (CD8+) and natural killer cells that fight the tumor. Some chemotherapy drugs may also support the maturation of dendritic cells, which initiate the immune response. This mechanism is the basis for studying metronomic chemotherapy together with immunotherapies.<\/p><h3>3. Continuous pressure on resistant tumor cells<\/h3><p>Resistant tumor cells can recover during the long breaks of high-dose treatment. Because the metronomic approach applies pressure without breaks, it gives these cells no chance to regrow. In addition, because vascular cells are genetically more stable than tumor cells, resistance to treatment targeting them may develop later.<\/p><h3>4. Tumor dormancy and cellular senescence<\/h3><p>According to some approaches, metronomic chemotherapy may also trigger processes such as &#8220;tumor dormancy&#8221; and cellular senescence, which stop tumor cells from dividing. These effects may help the disease remain stable for months.<\/p><h2>The Difference Between Metronomic and Standard Chemotherapy<\/h2><p>The two approaches differ not only in dose but also in their target and how they are given. The table below summarizes the main differences:<\/p><figure class=\"wp-block-table\"><table><thead><tr><th>Feature<\/th><th>Standard (MTD) Chemotherapy<\/th><th>Metronomic Chemotherapy<\/th><\/tr><\/thead><tbody><tr><td>Dose<\/td><td>Close to the maximum tolerated dose<\/td><td>About one-tenth to one-third of the MTD<\/td><\/tr><tr><td>Frequency<\/td><td>Usually every 1-3 weeks, with breaks<\/td><td>Daily or weekly, uninterrupted<\/td><\/tr><tr><td>Route<\/td><td>Mostly intravenous<\/td><td>Mostly oral<\/td><\/tr><tr><td>Main target<\/td><td>Directly killing tumor cells<\/td><td>Blood vessel growth and the tumor microenvironment<\/td><\/tr><tr><td>Side effects<\/td><td>More marked; supportive care may be needed<\/td><td>Generally milder<\/td><\/tr><tr><td>Hospital admission<\/td><td>Often needed<\/td><td>Not needed in most cases<\/td><\/tr><\/tbody><\/table><\/figure><p>An important distinction is that it should not be confused with dose-dense chemotherapy. The dose-dense approach shortens the intervals but keeps the dose high. The metronomic approach lowers the dose and never interrupts it. The two strategies have different biological targets and side effect profiles. For a detailed comparison, see <a href=\"\/en\/metronomic-vs-standard-chemotherapy\/\">metronomic vs standard chemotherapy<\/a>.<\/p><h2>Which Drugs Are Used in Metronomic Chemotherapy?<\/h2><p>Metronomic chemotherapy is not a single protocol but a dosing philosophy. Different drugs can be used alone or together at low, continuous doses. The components most often mentioned in the scientific literature and clinical practice are:<\/p><ul><li><strong>Cyclophosphamide:<\/strong> the most widely used agent, taken by mouth at low daily doses. It has been evaluated in tumors such as ovarian, breast and pancreatic cancer.<\/li><li><strong>Methotrexate:<\/strong> a combination component used with cyclophosphamide at low weekly doses, especially in metastatic breast cancer.<\/li><li><strong>Capecitabine:<\/strong> an oral option that can be given at lower fixed doses over a long period; it requires monitoring for skin toxicity.<\/li><li><strong>Vinorelbine:<\/strong> can be used as several small doses a week, especially in older or frail patients.<\/li><li><strong>Anti-VEGF agents (for example bevacizumab):<\/strong> can be added to metronomic chemotherapy to strengthen vascular suppression.<\/li><li><strong>Immunotherapy (for example pembrolizumab):<\/strong> being studied in combination regimens to support the immune response.<\/li><\/ul><p>Which drug is used, at what dose and on what schedule varies from center to center and from patient to patient. These decisions are always made by the medical oncologist after assessing the type and stage of the disease and the patient&#8217;s general condition. The information on this page is not a prescription. For each drug in detail, see <a href=\"\/en\/metronomic-chemotherapy-drugs\/\">metronomic chemotherapy drugs<\/a>.<\/p><h2>Which Cancers Is Metronomic Chemotherapy Used For?<\/h2><p>Metronomic chemotherapy has been studied especially in solid tumors that depend on blood vessel growth. The main clinical areas are:<\/p><h3>Ovarian cancer<\/h3><p>Recurrent, platinum-resistant ovarian cancer is one of the areas where metronomic chemotherapy was adopted earliest. In these patients, metronomic cyclophosphamide has been evaluated alone or together with anti-VEGF drugs that suppress vessel growth. Combination studies with anti-VEGF reported that the disease could be kept under control without progression for six months or longer in a meaningful proportion of patients.<\/p><p>In addition, studies of a three-drug approach using metronomic cyclophosphamide with anti-VEGF and immunotherapy reported objective response rates in the range of about 40 to 50 percent, with the disease progressing-free for a median of about ten months. Real-world analyses in older and heavily pretreated patients also found clinical benefit rates in a similar range, with treatment generally well tolerated. These results point to the potential of the metronomic approach in ovarian cancer to suppress the disease without harming quality of life.<\/p><h3>Metastatic breast cancer<\/h3><p>In metastatic breast cancer, the combination of metronomic cyclophosphamide and methotrexate has long been studied. When a drug that suppresses vessel growth (bevacizumab) was added to this regimen, the time the disease spent without progression was reported to lengthen; however, a clear difference in overall survival was not shown in every study. Older studies with metronomic cyclophosphamide and methotrexate found clinical benefit rates of about 30 to 40 percent, meaning the disease could be kept stable for at least six months in a significant proportion of patients.<\/p><p>In breast cancer, the aim of the metronomic approach is less rapid tumor shrinkage than keeping the disease chronically stable and delaying progression while preserving quality of life. It is therefore considered a meaningful option especially for patients whose hormonal options are exhausted and whose bone marrow reserve is fragile, but who should not be left without any treatment.<\/p><h3>Pancreatic cancer<\/h3><p>Treatment options are limited in advanced or metastatic pancreatic cancer. In selected patients whose disease was controlled with first-line treatment and remained stable for at least a few months, an oral metronomic cyclophosphamide-based maintenance approach was reported to lengthen the time without progression and overall survival, with a low side effect profile.<\/p><p>Although data in this area are still early and not yet mature through large randomized trials, the approach is increasingly discussed in the debate over &#8220;should we pause treatment or continue with gentle pressure?&#8221; In pancreatic cancer, every decision is made by the medical oncologist according to the patient&#8217;s individual situation.<\/p><p>Head and neck cancers, soft tissue sarcomas and some other solid tumors are also areas where the metronomic approach has been studied. Because every patient&#8217;s situation is different, whether this treatment is suitable can only be decided after a detailed oncologic assessment. For more on each cancer type, see <a href=\"\/en\/metronomic-chemotherapy-cancer-types\/\">which cancers metronomic chemotherapy is used for<\/a>.<\/p><h2>Metronomic Chemotherapy and Combination Treatments<\/h2><p>Metronomic chemotherapy is often planned not on its own but with other treatments that strengthen its effect. When low-dose cyclophosphamide&#8217;s suppression of vessel growth is combined with anti-VEGF drugs cutting off the vascular signal, two-way pressure can be applied to the tumor&#8217;s supply bed. This combination has contributed to the time without progression, especially in the ovarian cancer data.<\/p><p>The second important combination is between metronomic chemotherapy and immunotherapy. By reducing the regulatory T cells that suppress immunity, low-dose cyclophosphamide can make the tumor microenvironment more open to immune attack. This may support the effect of immunotherapy drugs that release the immune brake (for example pembrolizumab). The three-drug approach in ovarian cancer, combining a drug that suppresses vessel growth, metronomic cyclophosphamide and immunotherapy, is one example of this synergy in the clinic.<\/p><p>Which combination is used, in what order and in which patient is a complex decision, made only by the medical oncologist after assessing the characteristics of the disease and the patient&#8217;s general condition together.<\/p><h2>Who Is Metronomic Chemotherapy Suitable For?<\/h2><p>Metronomic chemotherapy is not suitable for every patient and does not replace standard treatment. The patient profiles for whom this approach is especially considered in the scientific literature and clinical practice can be summarized as follows:<\/p><ul><li>Patients with limited performance status whose general condition cannot tolerate high-dose treatment<\/li><li>Patients who have received several lines of treatment and whose options have narrowed<\/li><li>Patients with a fragile bone marrow reserve who would struggle to tolerate severe toxicity<\/li><li>Situations in which controlled pressure is the aim and leaving the disease entirely untreated is not desired<\/li><li>Selected patients in whom synergy with immunotherapy is expected<\/li><\/ul><p>In contrast, in patients with a very rapidly progressing tumor burden that directly threatens organ function, metronomic chemotherapy alone may be insufficient; faster-acting treatments may be needed. The suitability decision always requires an individual assessment.<\/p><h2>Side Effects of Metronomic Chemotherapy<\/h2><p>Metronomic chemotherapy generally has a milder side effect profile than standard chemotherapy, but this does not mean it has no side effects. Because the doses are low, severe (grade 3-4) side effects are less common. Common effects include:<\/p><ul><li>A fall in blood counts (leukopenia, lymphopenia); severe levels are relatively uncommon<\/li><li>Fatigue, mild nausea and diarrhea; mostly manageable<\/li><li>High blood pressure and protein in the urine with regimens containing anti-VEGF<\/li><li>Skin symptoms such as hand-foot syndrome with capecitabine<\/li><\/ul><p>With long-term low-dose use, theoretical risks such as cumulative bone marrow suppression and bladder irritation are also taken into account. Regular blood counts and urine tests throughout treatment are therefore important. Most side effects can be managed with dose adjustment, short breaks and supportive treatment. Effects common with standard chemotherapy, such as hair loss and severe nausea, are generally less marked with the metronomic approach.<\/p><p>A low side effect profile is one of the most important advantages of metronomic chemotherapy. It allows treatment to be continued even in older or frail patients. However, &#8220;milder&#8221; does not mean &#8220;risk-free&#8221;; the expected side effects and monitoring plan for each patient are explained in detail by the doctor before treatment starts. Any new symptom should be reported to the treatment team without delay. For a full account, see <a href=\"\/en\/metronomic-chemotherapy-side-effects\/\">metronomic chemotherapy side effects<\/a>.<\/p><h2>The Place of Metronomic Chemotherapy in Treatment<\/h2><p>Metronomic chemotherapy is often seen as &#8220;a mild form of classic chemotherapy,&#8221; but strategically it serves a different purpose. Rather than rapid tumor shrinkage, it is a sustained-pressure treatment that dries up the vascular bed, loosens immune suppression and wears the tumor down biologically. For this reason, in many cases it is positioned not as a curative method but as a maintenance or bridging strategy that keeps the disease under control.<\/p><p>This positioning means that a high dose is not always necessary. For some patients, continuous but gentle pressure with manageable side effects may be more meaningful for quality of life and time without progression. Especially where leaving the disease entirely untreated is not desired but intensive treatment is not appropriate either, the metronomic approach offers a valuable option.<\/p><h2>Is Metronomic Chemotherapy Effective? The Scientific Evidence<\/h2><p>The foundations of metronomic chemotherapy rest on pioneering studies showing that low-dose chemotherapy can target blood vessel growth. The study by Hanahan and colleagues published in the <em>Journal of Clinical Investigation<\/em> in 2000 showed that cytotoxic drugs given on a metronomic (regular, uninterrupted) schedule could target tumor vasculature. In the same year, Klement and colleagues reported that combining continuous low-dose vinblastine with a treatment targeting the VEGF receptor achieved tumor regression without marked toxicity in an experimental model.<\/p><p>Reviews in the following years showed that metronomic chemotherapy is a multi-targeted treatment that not only suppresses vessel growth but also works through additional mechanisms such as immune regulation and tumor dormancy. The 2014 review by Maiti evaluated this multi-targeted effect and the low side effect profile in detail. A recent review published in <em>Theranostics<\/em> in 2024 summarized how the approach has evolved from salvage treatment in metastatic disease toward maintenance treatment in high-risk patients.<\/p><p>ONCOMSI&#8217;s own clinical observations also contribute to this literature. In the 2026 case report by Assoc. Prof. Mehmet Salih \u0130yikesici (\u0130yikesici MS. <em>Curr Oncol.<\/em> 2026;33(8):489. PMID 42645394), a protocol described by the authors as metronomic in style was used in a patient with drug-resistant advanced pancreatic adenocarcinoma, with cytotoxic drugs given at <strong>no more than 50% of their conventional doses<\/strong> and <strong>every 14 days<\/strong>. One month later, PET\/CT showed a <strong>63.7% reduction<\/strong> in SUVmax (from 18.2 to 6.6), and performance status improved from <strong>ECOG PS 2 to PS 0<\/strong>. Treatment-related side effects were limited to Grade 1 nausea, Grade 1 vomiting and thrombocytopenia, with no Grade 2 or higher non-hematologic toxicity. As a single, uncontrolled observation, these findings do not establish causation; the authors state that the results need to be confirmed by prospective, controlled studies.<\/p><p>Although this body of work is encouraging, metronomic chemotherapy is not a curative method on its own in every situation. Much of the research is at an early phase, and studies continue to determine the most suitable drug, dose and timing for each patient. At ONCOMSI, this literature is considered as part of an individual and realistic assessment for each patient; no definite result or guarantee is promised for any treatment.<\/p><h2>ONCOMSI&#8217;s Approach to Metronomic Chemotherapy<\/h2><p>ONCOMSI is an international medical oncology center based in Istanbul, Turkey, and considers metronomic chemotherapy not as a stand-alone intervention but as one component of an integrative treatment roadmap. In this approach, the medical oncologist is the conductor of the treatment: coordinating every step from diagnosis to recovery and deciding how metronomic chemotherapy should be integrated with other methods when needed.<\/p><p>The center&#8217;s chief physician, Assoc. Prof. Mehmet Salih \u0130yikesici, is a medical oncologist experienced in metabolically controlled approaches and integrative oncology. Our specialist team, with years of clinical experience, assesses each patient&#8217;s situation individually and creates a personalized treatment plan. For more about Assoc. Prof. \u0130yikesici, see <a href=\"\/en\/team\/assoc-prof-dr-mehmet-salih-iyikesici\/\">Assoc. Prof. Mehmet Salih \u0130yikesici<\/a>.<\/p><p>At ONCOMSI, when appropriate, metronomic chemotherapy can be planned together with other treatment protocols, above all <a href=\"\/en\/treatments\/metabolically-controlled-oncologic-therapy\/\">Metabolically Controlled Oncologic Therapy (MCOT)<\/a>. This integrative view aims for fewer side effects and a more sustainable treatment process.<\/p><h2>How Does the Metronomic Chemotherapy Process Work in Istanbul?<\/h2><p>For patients who come to ONCOMSI in Istanbul, the metronomic chemotherapy process follows a planned patient journey from start to finish:<\/p><ol><li><strong>Initial assessment and consultation:<\/strong> The patient&#8217;s diagnosis, stage, previous treatments and general condition are reviewed in detail. Existing medical records and imaging are assessed.<\/li><li><strong>Personalized plan:<\/strong> The medical oncologist decides whether metronomic chemotherapy is suitable and which drug schedule to choose. The other components of the integrative protocol are planned when needed.<\/li><li><strong>Starting treatment:<\/strong> Drugs are mostly given by mouth in a routine that can be continued at home. In most cases hospital admission is not needed.<\/li><li><strong>Monitoring and follow-up:<\/strong> Treatment response and side effects are tracked with regular blood counts, urine tests and imaging; the dose is adjusted when needed.<\/li><\/ol><p>This process in Istanbul is planned to be accessible for patients from within the city, from other cities and from abroad. Because metronomic chemotherapy can be given orally and as an outpatient, patients can continue their daily lives as much as possible. For process details for patients from abroad, see <a href=\"\/en\/metronomic-chemotherapy-turkey\/\">metronomic chemotherapy in Turkey<\/a> and the <a href=\"\/en\/international-patients\/\">international patients<\/a> page.<\/p><p>Arranging the supply of oral drugs and regular blood monitoring is also part of this process. Our team in Istanbul keeps the patient and their loved ones informed throughout treatment and stays with them at every step. For appointments and contact, use the <a href=\"\/en\/contact\/\">contact<\/a> page.<\/p><h2>Frequently Asked Questions<\/h2><div class=\"wp-block-rank-math-faq-block\"><div class=\"rank-math-list\"><div class=\"rank-math-list-item\">\u00a0<\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-7af25fd elementor-widget elementor-widget-accordion\" data-id=\"7af25fd\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"accordion.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-accordion\">\n\t\t\t\t\t\t\t<div class=\"elementor-accordion-item\">\n\t\t\t\t\t<h3 id=\"elementor-tab-title-1281\" class=\"elementor-tab-title\" data-tab=\"1\" role=\"button\" aria-controls=\"elementor-tab-content-1281\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon elementor-accordion-icon-right\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-closed\"><i class=\"flaticon flaticon-view\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-opened\"><i class=\"flaticon flaticon-hide\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-accordion-title\" tabindex=\"0\">What is metronomic chemotherapy?<\/a>\n\t\t\t\t\t<\/h3>\n\t\t\t\t\t<div id=\"elementor-tab-content-1281\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"1\" role=\"region\" aria-labelledby=\"elementor-tab-title-1281\"><div class=\"rank-math-list-item\"><div class=\"rank-math-answer\"><p>Metronomic chemotherapy is a cancer treatment approach based on giving chemotherapy drugs at very low doses instead of standard high doses, continuously or at very short intervals, over a long period. The aim is to suppress the vessels feeding the tumor and keep the disease under control while preserving quality of life.<\/p><\/div><\/div><div class=\"rank-math-list-item\">\u00a0<\/div><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-accordion-item\">\n\t\t\t\t\t<h3 id=\"elementor-tab-title-1282\" class=\"elementor-tab-title\" data-tab=\"2\" role=\"button\" aria-controls=\"elementor-tab-content-1282\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon elementor-accordion-icon-right\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-closed\"><i class=\"flaticon flaticon-view\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-opened\"><i class=\"flaticon flaticon-hide\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-accordion-title\" tabindex=\"0\">How is metronomic chemotherapy different from standard chemotherapy?<\/a>\n\t\t\t\t\t<\/h3>\n\t\t\t\t\t<div id=\"elementor-tab-content-1282\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"2\" role=\"region\" aria-labelledby=\"elementor-tab-title-1282\"><div class=\"rank-math-list-item\"><div class=\"rank-math-answer\"><p>Standard chemotherapy is given at high doses with breaks, mostly intravenously, and targets tumor cells directly. Metronomic chemotherapy is given at much lower doses, continuously and usually by mouth; its main target is the tumor&#8217;s blood vessel growth and microenvironment. Side effects are generally milder.<\/p><\/div><\/div><div class=\"rank-math-list-item\">\u00a0<\/div><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-accordion-item\">\n\t\t\t\t\t<h3 id=\"elementor-tab-title-1283\" class=\"elementor-tab-title\" data-tab=\"3\" role=\"button\" aria-controls=\"elementor-tab-content-1283\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon elementor-accordion-icon-right\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-closed\"><i class=\"flaticon flaticon-view\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-opened\"><i class=\"flaticon flaticon-hide\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-accordion-title\" tabindex=\"0\">Does metronomic chemotherapy cause hair loss?<\/a>\n\t\t\t\t\t<\/h3>\n\t\t\t\t\t<div id=\"elementor-tab-content-1283\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"3\" role=\"region\" aria-labelledby=\"elementor-tab-title-1283\"><div class=\"rank-math-list-item\"><div class=\"rank-math-answer\"><p>Because the doses used in metronomic chemotherapy are low, the heavy hair loss common with standard chemotherapy is generally less marked. Even so, it can vary with the drug and the person. Your doctor will go over the expected side effects with you before treatment.<\/p><\/div><\/div><div class=\"rank-math-list-item\">\u00a0<\/div><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-accordion-item\">\n\t\t\t\t\t<h3 id=\"elementor-tab-title-1284\" class=\"elementor-tab-title\" data-tab=\"4\" role=\"button\" aria-controls=\"elementor-tab-content-1284\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon elementor-accordion-icon-right\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-closed\"><i class=\"flaticon flaticon-view\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-opened\"><i class=\"flaticon flaticon-hide\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-accordion-title\" tabindex=\"0\">Can metronomic chemotherapy be taken at home and by mouth?<\/a>\n\t\t\t\t\t<\/h3>\n\t\t\t\t\t<div id=\"elementor-tab-content-1284\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"4\" role=\"region\" aria-labelledby=\"elementor-tab-title-1284\"><div class=\"rank-math-list-item\"><div class=\"rank-math-answer\"><p>In metronomic chemotherapy, drugs are mostly given by mouth and in most cases hospital admission is not needed. This allows treatment to be continued largely at home as an outpatient. The details are planned by the doctor according to the chosen drug and the patient&#8217;s condition.<\/p><\/div><\/div><div class=\"rank-math-list-item\">\u00a0<\/div><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-accordion-item\">\n\t\t\t\t\t<h3 id=\"elementor-tab-title-1285\" class=\"elementor-tab-title\" data-tab=\"5\" role=\"button\" aria-controls=\"elementor-tab-content-1285\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon elementor-accordion-icon-right\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-closed\"><i class=\"flaticon flaticon-view\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-opened\"><i class=\"flaticon flaticon-hide\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-accordion-title\" tabindex=\"0\">Which cancers is metronomic chemotherapy used for?<\/a>\n\t\t\t\t\t<\/h3>\n\t\t\t\t\t<div id=\"elementor-tab-content-1285\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"5\" role=\"region\" aria-labelledby=\"elementor-tab-title-1285\"><div class=\"rank-math-list-item\"><div class=\"rank-math-answer\"><p>Metronomic chemotherapy has been studied especially in solid tumors that depend on blood vessel growth. The main areas are recurrent ovarian cancer, metastatic breast cancer and advanced pancreatic cancer. Head and neck cancers and some sarcomas are also among the areas studied.<\/p><\/div><\/div><div class=\"rank-math-list-item\">\u00a0<\/div><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-accordion-item\">\n\t\t\t\t\t<h3 id=\"elementor-tab-title-1286\" class=\"elementor-tab-title\" data-tab=\"6\" role=\"button\" aria-controls=\"elementor-tab-content-1286\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon elementor-accordion-icon-right\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-closed\"><i class=\"flaticon flaticon-view\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-opened\"><i class=\"flaticon flaticon-hide\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-accordion-title\" tabindex=\"0\">Who is metronomic chemotherapy suitable for?<\/a>\n\t\t\t\t\t<\/h3>\n\t\t\t\t\t<div id=\"elementor-tab-content-1286\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"6\" role=\"region\" aria-labelledby=\"elementor-tab-title-1286\"><div class=\"rank-math-list-item\"><div class=\"rank-math-answer\"><p>This approach is considered especially for patients who would struggle to tolerate high-dose treatment, who have received several lines of treatment, or for whom disease control with preserved quality of life is the goal. It may be insufficient on its own for very rapidly progressing tumors. Suitability is always determined individually by the doctor.<\/p><\/div><\/div><div class=\"rank-math-list-item\">\u00a0<\/div><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-accordion-item\">\n\t\t\t\t\t<h3 id=\"elementor-tab-title-1287\" class=\"elementor-tab-title\" data-tab=\"7\" role=\"button\" aria-controls=\"elementor-tab-content-1287\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon elementor-accordion-icon-right\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-closed\"><i class=\"flaticon flaticon-view\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-opened\"><i class=\"flaticon flaticon-hide\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-accordion-title\" tabindex=\"0\">Does metronomic chemotherapy require hospital admission?<\/a>\n\t\t\t\t\t<\/h3>\n\t\t\t\t\t<div id=\"elementor-tab-content-1287\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"7\" role=\"region\" aria-labelledby=\"elementor-tab-title-1287\"><div class=\"rank-math-list-item\"><div class=\"rank-math-answer\"><p>Because most metronomic chemotherapy regimens can be given orally and as an outpatient, hospital admission is not needed. Unlike standard chemotherapy, treatment can be continued within daily life. Regular monitoring visits remain important.<\/p><\/div><\/div><div class=\"rank-math-list-item\">\u00a0<\/div><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-accordion-item\">\n\t\t\t\t\t<h3 id=\"elementor-tab-title-1288\" class=\"elementor-tab-title\" data-tab=\"8\" role=\"button\" aria-controls=\"elementor-tab-content-1288\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon elementor-accordion-icon-right\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-closed\"><i class=\"flaticon flaticon-view\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-opened\"><i class=\"flaticon flaticon-hide\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-accordion-title\" tabindex=\"0\">Which drugs are used in metronomic chemotherapy?<\/a>\n\t\t\t\t\t<\/h3>\n\t\t\t\t\t<div id=\"elementor-tab-content-1288\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"8\" role=\"region\" aria-labelledby=\"elementor-tab-title-1288\"><div class=\"rank-math-list-item\"><div class=\"rank-math-answer\"><p>The most commonly used agent is low-dose oral cyclophosphamide. Methotrexate, capecitabine and vinorelbine can also be used. In some cases anti-VEGF agents that suppress vessel growth or immunotherapy drugs may be added to the combination. The drug is chosen by the medical oncologist.<\/p><\/div><\/div><div class=\"rank-math-list-item\">\u00a0<\/div><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-accordion-item\">\n\t\t\t\t\t<h3 id=\"elementor-tab-title-1289\" class=\"elementor-tab-title\" data-tab=\"9\" role=\"button\" aria-controls=\"elementor-tab-content-1289\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon elementor-accordion-icon-right\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-closed\"><i class=\"flaticon flaticon-view\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-opened\"><i class=\"flaticon flaticon-hide\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-accordion-title\" tabindex=\"0\">How does metronomic chemotherapy affect the immune system?<\/a>\n\t\t\t\t\t<\/h3>\n\t\t\t\t\t<div id=\"elementor-tab-content-1289\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"9\" role=\"region\" aria-labelledby=\"elementor-tab-title-1289\"><div class=\"rank-math-list-item\"><div class=\"rank-math-answer\"><p>Metronomic chemotherapy, especially low-dose cyclophosphamide, can reduce the regulatory T cells that suppress immunity and increase the activity of the immune cells that fight the tumor. This is one of the main reasons it is studied together with immunotherapies.<\/p><\/div><\/div><div class=\"rank-math-list-item\">\u00a0<\/div><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-accordion-item\">\n\t\t\t\t\t<h3 id=\"elementor-tab-title-12810\" class=\"elementor-tab-title\" data-tab=\"10\" role=\"button\" aria-controls=\"elementor-tab-content-12810\" aria-expanded=\"false\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon elementor-accordion-icon-right\" aria-hidden=\"true\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-closed\"><i class=\"flaticon flaticon-view\"><\/i><\/span>\n\t\t\t\t\t\t\t\t<span class=\"elementor-accordion-icon-opened\"><i class=\"flaticon flaticon-hide\"><\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-accordion-title\" tabindex=\"0\">Where can I apply for metronomic chemotherapy in Istanbul?<\/a>\n\t\t\t\t\t<\/h3>\n\t\t\t\t\t<div id=\"elementor-tab-content-12810\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"10\" role=\"region\" aria-labelledby=\"elementor-tab-title-12810\"><div class=\"wp-block-rank-math-faq-block\"><div class=\"rank-math-list\"><div class=\"rank-math-list-item\"><div class=\"rank-math-answer\"><p>You can request an appointment with the ONCOMSI medical oncology team for a metronomic chemotherapy assessment in Istanbul. At the initial consultation your diagnosis and existing medical records are reviewed and it is determined whether a suitable treatment plan can be created for you.<\/p><\/div><\/div><\/div><\/div><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t<script type=\"application\/ld+json\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is metronomic chemotherapy?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"<div class=\\\"rank-math-list-item\\\"><div class=\\\"rank-math-answer\\\"><p>Metronomic chemotherapy is a cancer treatment approach based on giving chemotherapy drugs at very low doses instead of standard high doses, continuously or at very short intervals, over a long period. The aim is to suppress the vessels feeding the tumor and keep the disease under control while preserving quality of life.<\\\/p><\\\/div><\\\/div><div class=\\\"rank-math-list-item\\\">\\u00a0<\\\/div>\"}},{\"@type\":\"Question\",\"name\":\"How is metronomic chemotherapy different from standard chemotherapy?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"<div class=\\\"rank-math-list-item\\\"><div class=\\\"rank-math-answer\\\"><p>Standard chemotherapy is given at high doses with breaks, mostly intravenously, and targets tumor cells directly. Metronomic chemotherapy is given at much lower doses, continuously and usually by mouth; its main target is the tumor&#8217;s blood vessel growth and microenvironment. Side effects are generally milder.<\\\/p><\\\/div><\\\/div><div class=\\\"rank-math-list-item\\\">\\u00a0<\\\/div>\"}},{\"@type\":\"Question\",\"name\":\"Does metronomic chemotherapy cause hair loss?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"<div class=\\\"rank-math-list-item\\\"><div class=\\\"rank-math-answer\\\"><p>Because the doses used in metronomic chemotherapy are low, the heavy hair loss common with standard chemotherapy is generally less marked. Even so, it can vary with the drug and the person. Your doctor will go over the expected side effects with you before treatment.<\\\/p><\\\/div><\\\/div><div class=\\\"rank-math-list-item\\\">\\u00a0<\\\/div>\"}},{\"@type\":\"Question\",\"name\":\"Can metronomic chemotherapy be taken at home and by mouth?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"<div class=\\\"rank-math-list-item\\\"><div class=\\\"rank-math-answer\\\"><p>In metronomic chemotherapy, drugs are mostly given by mouth and in most cases hospital admission is not needed. This allows treatment to be continued largely at home as an outpatient. The details are planned by the doctor according to the chosen drug and the patient&#8217;s condition.<\\\/p><\\\/div><\\\/div><div class=\\\"rank-math-list-item\\\">\\u00a0<\\\/div>\"}},{\"@type\":\"Question\",\"name\":\"Which cancers is metronomic chemotherapy used for?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"<div class=\\\"rank-math-list-item\\\"><div class=\\\"rank-math-answer\\\"><p>Metronomic chemotherapy has been studied especially in solid tumors that depend on blood vessel growth. The main areas are recurrent ovarian cancer, metastatic breast cancer and advanced pancreatic cancer. Head and neck cancers and some sarcomas are also among the areas studied.<\\\/p><\\\/div><\\\/div><div class=\\\"rank-math-list-item\\\">\\u00a0<\\\/div>\"}},{\"@type\":\"Question\",\"name\":\"Who is metronomic chemotherapy suitable for?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"<div class=\\\"rank-math-list-item\\\"><div class=\\\"rank-math-answer\\\"><p>This approach is considered especially for patients who would struggle to tolerate high-dose treatment, who have received several lines of treatment, or for whom disease control with preserved quality of life is the goal. It may be insufficient on its own for very rapidly progressing tumors. Suitability is always determined individually by the doctor.<\\\/p><\\\/div><\\\/div><div class=\\\"rank-math-list-item\\\">\\u00a0<\\\/div>\"}},{\"@type\":\"Question\",\"name\":\"Does metronomic chemotherapy require hospital admission?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"<div class=\\\"rank-math-list-item\\\"><div class=\\\"rank-math-answer\\\"><p>Because most metronomic chemotherapy regimens can be given orally and as an outpatient, hospital admission is not needed. Unlike standard chemotherapy, treatment can be continued within daily life. Regular monitoring visits remain important.<\\\/p><\\\/div><\\\/div><div class=\\\"rank-math-list-item\\\">\\u00a0<\\\/div>\"}},{\"@type\":\"Question\",\"name\":\"Which drugs are used in metronomic chemotherapy?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"<div class=\\\"rank-math-list-item\\\"><div class=\\\"rank-math-answer\\\"><p>The most commonly used agent is low-dose oral cyclophosphamide. Methotrexate, capecitabine and vinorelbine can also be used. In some cases anti-VEGF agents that suppress vessel growth or immunotherapy drugs may be added to the combination. The drug is chosen by the medical oncologist.<\\\/p><\\\/div><\\\/div><div class=\\\"rank-math-list-item\\\">\\u00a0<\\\/div>\"}},{\"@type\":\"Question\",\"name\":\"How does metronomic chemotherapy affect the immune system?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"<div class=\\\"rank-math-list-item\\\"><div class=\\\"rank-math-answer\\\"><p>Metronomic chemotherapy, especially low-dose cyclophosphamide, can reduce the regulatory T cells that suppress immunity and increase the activity of the immune cells that fight the tumor. This is one of the main reasons it is studied together with immunotherapies.<\\\/p><\\\/div><\\\/div><div class=\\\"rank-math-list-item\\\">\\u00a0<\\\/div>\"}},{\"@type\":\"Question\",\"name\":\"Where can I apply for metronomic chemotherapy in Istanbul?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"<div class=\\\"wp-block-rank-math-faq-block\\\"><div class=\\\"rank-math-list\\\"><div class=\\\"rank-math-list-item\\\"><div class=\\\"rank-math-answer\\\"><p>You can request an appointment with the ONCOMSI medical oncology team for a metronomic chemotherapy assessment in Istanbul. At the initial consultation your diagnosis and existing medical records are reviewed and it is determined whether a suitable treatment plan can be created for you.<\\\/p><\\\/div><\\\/div><\\\/div><\\\/div>\"}}]}<\/script>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-7ef6f00 p-mb-0 elementor-widget elementor-widget-text-editor\" data-id=\"7ef6f00\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h2>Appointments and Contact<\/h2><p>Only an in-person medical assessment can determine whether metronomic chemotherapy is suitable in your case. At ONCOMSI, metronomic chemotherapy is not planned on its own; when appropriate it is planned together with other protocols, above all <a href=\"\/en\/treatments\/metabolically-controlled-oncologic-therapy\/\">Metabolically Controlled Oncologic Therapy (MCOT)<\/a>, <strong>under the coordination of the medical oncologist<\/strong>. Our Istanbul-based team reviews your diagnosis and existing medical records at the initial consultation and determines whether a suitable treatment plan can be created for you. For a personal assessment, <a href=\"\/en\/contact\/\">get in touch to request an appointment<\/a>.<\/p><div class=\"wp-block-buttons\"><div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" href=\"\/en\/contact\/\">Request a Consultation<\/a><\/div><\/div><p><em>This page is for informational purposes only. Please consult your doctor for diagnosis, treatment, and personal health decisions.<\/em><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-a430a4c elementor-widget elementor-widget-our-team-single\" data-id=\"a430a4c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"our-team-single.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\n\n       <div class=\"swiper team-swiper\">\n      <div class=\"swiper-wrapper\">\n\n                          <div class=\"swiper-slide\">\n               \n\n                            <div class=\"team-member style-2\">\n                        <div class=\"team-images\">\n            <img fetchpriority=\"high\" decoding=\"async\" width=\"1214\" height=\"1579\" src=\"https:\/\/oncomsi.com\/wp-content\/uploads\/2024\/11\/doc-dr-mehmet-salih-iyikesici.webp\" class=\"attachment-post-thumbnail size-post-thumbnail wp-post-image\" alt=\"Assoc. Prof. Dr. Mehmet Salih \u0130yikesici - Medical Oncologist\" srcset=\"https:\/\/oncomsi.com\/wp-content\/uploads\/2024\/11\/doc-dr-mehmet-salih-iyikesici.webp 1214w, https:\/\/oncomsi.com\/wp-content\/uploads\/2024\/11\/doc-dr-mehmet-salih-iyikesici-231x300.webp 231w, https:\/\/oncomsi.com\/wp-content\/uploads\/2024\/11\/doc-dr-mehmet-salih-iyikesici-787x1024.webp 787w, https:\/\/oncomsi.com\/wp-content\/uploads\/2024\/11\/doc-dr-mehmet-salih-iyikesici-768x999.webp 768w, https:\/\/oncomsi.com\/wp-content\/uploads\/2024\/11\/doc-dr-mehmet-salih-iyikesici-1181x1536.webp 1181w, https:\/\/oncomsi.com\/wp-content\/uploads\/2024\/11\/doc-dr-mehmet-salih-iyikesici-600x780.webp 600w\" sizes=\"(max-width: 1214px) 100vw, 1214px\" \/>          <\/div>\n                        <div class=\"team-desc\">\n                            <span>Medical Oncologist<\/span>\n                        <p class=\"h4\"><a href=\"https:\/\/oncomsi.com\/en\/team\/assoc-prof-dr-mehmet-salih-iyikesici\/\">Assoc. Prof. Dr. Mehmet Salih \u0130yikesici<\/a><\/p>\n                        \n                        <ul class=\"list-unstyled team-media\">\n                <li><i class=\"bi bi-telephone-outbound\"><\/i><a href=\"tel:+90 212 385 31 00\">+90 212 385 31 00<\/a>\n                <\/li>\n                <li><i class=\"bi bi-envelope\"><\/i><a href=\"mailto:info@oncomsi.com\">info@oncomsi.com<\/a>\n                <\/li>\n                <\/ul>\n                <ul class=\"team-social-icon list-inline mb-0\">\n                <li><a href=\"https:\/\/www.instagram.com\/oncomsi.oncologycenter\" rel=\"nofollow noopener\" target=\"_blank\"><i class=\"flaticon-instagram\"><\/i><\/a>\n                <\/li>\n                <li><a href=\"https:\/\/www.youtube.com\/@oncomsi\" rel=\"nofollow noopener\" target=\"_blank\"><i class=\"bi bi-youtube\"><\/i><\/a>\n                <\/li>\n                <li><a href=\"https:\/\/www.facebook.com\/oncomsi.oncologycenter\" rel=\"nofollow noopener\" target=\"_blank\"><i class=\"flaticon-facebook-app-symbol\"><\/i><\/a>\n                <\/li>\n                <li><a href=\"https:\/\/www.linkedin.com\/company\/oncomsi\/\" rel=\"nofollow noopener\" target=\"_blank\"><i class=\"flaticon-linkedin\"><\/i><\/a>\n                <\/li>\n                <\/ul>\n                        <\/div>\n        <\/div>\n                \n          <\/div>\n                       <\/div>\n        \n     <\/div>\n         \n        \t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Metronomic chemotherapy involves giving certain medicines at low doses on a frequent, regular schedule. Its suitability depends on the cancer\u2019s characteristics, previous treatments, and the individual\u2019s overall health and treatment goals.<\/p>\n","protected":false},"featured_media":7519,"parent":0,"comment_status":"open","ping_status":"closed","template":"","tedavi-kategorileri":[108],"class_list":["post-7518","services","type-services","status-publish","has-post-thumbnail","hentry","tedavi-kategorileri-treatment-protocols"],"acf":[],"_links":{"self":[{"href":"https:\/\/oncomsi.com\/en\/wp-json\/wp\/v2\/services\/7518","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oncomsi.com\/en\/wp-json\/wp\/v2\/services"}],"about":[{"href":"https:\/\/oncomsi.com\/en\/wp-json\/wp\/v2\/types\/services"}],"replies":[{"embeddable":true,"href":"https:\/\/oncomsi.com\/en\/wp-json\/wp\/v2\/comments?post=7518"}],"version-history":[{"count":12,"href":"https:\/\/oncomsi.com\/en\/wp-json\/wp\/v2\/services\/7518\/revisions"}],"predecessor-version":[{"id":8053,"href":"https:\/\/oncomsi.com\/en\/wp-json\/wp\/v2\/services\/7518\/revisions\/8053"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/oncomsi.com\/en\/wp-json\/wp\/v2\/media\/7519"}],"wp:attachment":[{"href":"https:\/\/oncomsi.com\/en\/wp-json\/wp\/v2\/media?parent=7518"}],"wp:term":[{"taxonomy":"tedavi-kategorileri","embeddable":true,"href":"https:\/\/oncomsi.com\/en\/wp-json\/wp\/v2\/tedavi-kategorileri?post=7518"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}